Comparison
Glepaglutide vs. Linaclotid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
no data
851199-59-2
Molecular weight
no data
1526.74 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
0
of which in humans
1
0
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Glepaglutide and Linaclotid?
- Glepaglutide is classified as "Research other", while Linaclotid is classified as "Research other". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Linaclotid?
- The highest available evidence level is "Human RCT" for Glepaglutide and "Human RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Linaclotid in Germany and the United States?
- Germany: Glepaglutide — Unapproved, Linaclotid — Prescription. United States: Glepaglutide — Unapproved, Linaclotid — Prescription. These are factual summaries with source and review date on the individual pages.